Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
12 pending office actions • 11 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
The George Washington University has 12 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 12 distinct examiners and 11 distinct art units, indicating broad examiner dispersion with some repeated art-unit assignment.
GRASMEDER, SARAH DYMPNA is the busiest examiner, with 1 pending matter. Counsel should use standardized portfolio review while adapting prosecution responses to the separate examiner relationships and examination settings.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (25%) |
| §103 only | 4 (33%) |
| §102 only | 1 (8%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 3 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASMEDER, SARAH DYMPNA | 1 | 72.0% | +33.7% |
| LUU, PHO M | 1 | 96.9% | +3.3% |
| IP, JASON M | 1 | 55.5% | +24.9% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.3% |
| PARK, EDWARD | 1 | 82.3% | +17.9% |
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| KANG, TAE-SIK | 1 | 58.5% | +27.7% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19072757 | SPINTRONIC ADAPTIVE APPROXIMATE MEMORY (SAAM) | LUU, PHO M | — |
| 18847605 | REAL TIME AUTOMATED NERVE IDENTIFICATION SYSTEM | PARK, EDWARD | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17159691 | ROBOT-AIDED SYSTEM AND METHOD FOR DIAGNOSIS OF AUTISM SPECTRUM DISORDER | ASGHAR, AMINAH | 112d overdue |
| 19065051 | HYPER-EXCITATION HYPERSPECTRAL IMAGING SYSTEM | IP, JASON M | 34d |
| 18653895 | COMPOSITIONS COMPRISING A ZIM3 EFFECTOR AND METHODS OF USE THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 18429316 | COMPOSITIONS FOR AND METHODS OF IMPROVING DIRECTED EVOLUTION OF BIOMOLECULES | PHAM, KHAI QUYNH TIEN | — |
| 18297565 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | METCALF, MATTHEW CURRAN | — |
| 17276081 | CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME | ALLEN, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773486 | PHOTOVOLTAIC RECEIVER FOR FREE-SPACE OPTICAL POWER BEAMING | KANG, TAE-SIK | 60d overdue |
| 19065051 | HYPER-EXCITATION HYPERSPECTRAL IMAGING SYSTEM | IP, JASON M | 34d |
| 19224405 | GUIDEWIRE FOR PREVENTION OF RETENTION AND METHODS OF USE AND MANUFACTURE THEREOF | GRASMEDER, SARAH DYMPNA | — |
| 18962917 | METHOD OF TREATING A MAMMAL WITH DIABETES ASSOCIATED KIDNEY DISEASE USING LOCAL ADMINISTRATION OF STEM CELLS WITH TRANSIENTLY REDUCED p53 | BERTOGLIO, VALARIE E | — |
| 18847605 | REAL TIME AUTOMATED NERVE IDENTIFICATION SYSTEM | PARK, EDWARD | — |
| 18653895 | COMPOSITIONS COMPRISING A ZIM3 EFFECTOR AND METHODS OF USE THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 18297565 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | METCALF, MATTHEW CURRAN | — |
| 17626013 | MODIFIED NATURAL KILLER CELLS AND METHODS OF USING THE SAME | MELCHIOR, JAMES RYLAND | — |
| Art Unit | Apps |
|---|---|
| 3797 | 2 |
| 3783 | 1 |
| 2824 | 1 |
| 1636 | 1 |
| 2675 | 1 |
| 1638 | 1 |
| 1684 | 1 |
| 1647 | 1 |
| 1728 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19224405 | GUIDEWIRE FOR PREVENTION OF RETENTION AND METHODS OF USE AND MANUFACTURE THEREOF | GRASMEDER, SARAH DYMPNA | 3783 | §103 | Non-Final OA | — | Pending | May 30, 2025 |
| 19072757 | SPINTRONIC ADAPTIVE APPROXIMATE MEMORY (SAAM) | LUU, PHO M | 2824 | §102 | Non-Final OA | — | Pending | Mar 06, 2025 |
| 19065051 | HYPER-EXCITATION HYPERSPECTRAL IMAGING SYSTEM | IP, JASON M | 3797 | §102§103§112 | Final Rejection | 34d | Pending | Feb 27, 2025 |
| 18962917 | METHOD OF TREATING A MAMMAL WITH DIABETES ASSOCIATED KIDNEY DISEASE USING LOCAL ADMINISTRATION OF STEM CELLS WITH TRANSIENTLY REDUCED p53 | BERTOGLIO, VALARIE E | 1636 | §103DP | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18847605 | REAL TIME AUTOMATED NERVE IDENTIFICATION SYSTEM | PARK, EDWARD | 2675 | §103 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18653895 | COMPOSITIONS COMPRISING A ZIM3 EFFECTOR AND METHODS OF USE THEREOF | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18429316 | COMPOSITIONS FOR AND METHODS OF IMPROVING DIRECTED EVOLUTION OF BIOMOLECULES | PHAM, KHAI QUYNH TIEN | 1684 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18297565 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | METCALF, MATTHEW CURRAN | 1647 | §103§112 | Final Rejection | — | Pending | Apr 07, 2023 |
| 17773486 | PHOTOVOLTAIC RECEIVER FOR FREE-SPACE OPTICAL POWER BEAMING | KANG, TAE-SIK | 1728 | §103 | Final Rejection | 60d overdue | Pending | Apr 29, 2022 |
| 17626013 | MODIFIED NATURAL KILLER CELLS AND METHODS OF USING THE SAME | MELCHIOR, JAMES RYLAND | 1644 | §103 | Non-Final OA | — | Pending | Jan 10, 2022 |
| 17276081 | CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME | ALLEN, MICHAEL D | 1671 | §101§112 | Non-Final OA | — | Pending | Mar 12, 2021 |
| 17159691 | ROBOT-AIDED SYSTEM AND METHOD FOR DIAGNOSIS OF AUTISM SPECTRUM DISORDER | ASGHAR, AMINAH | 3797 | §101§112 | Final Rejection | 112d overdue | Pending | Jan 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe George Washington University has 12 pending office actions as of October 2026, spread across 11 art units and 12 examiners.
Sarah Dympna Grasmeder has the most, with 1 of The George Washington University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
